Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19

被引：35
|
作者：
Giovannoni, Gavin [1 ]
机构：
[1] Barts & London Queen Marys Sch Med & Dent, Blizard Inst, 4 Newark St, London E1 2AT, England
来源：
MULTIPLE SCLEROSIS AND RELATED DISORDERS | 2020年 / 41卷
关键词：
OCRELIZUMAB;
D O I：
10.1016/j.msard.2020.102135
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [21] The emergence of follow-on disease-modifying therapies for multiple sclerosis
    Moss, Brandon P.
    Cohen, Jeffrey A.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (12) : 1560 - 1565
  • [22] Infections in Patients Receiving Multiple Sclerosis Disease-Modifying Therapies
    Elena Grebenciucova
    Amy Pruitt
    Current Neurology and Neuroscience Reports, 2017, 17
  • [23] Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD-20 therapies: A systematic review and meta-analysis
    Schiavetti, Irene
    Ponzano, Marta
    Signori, Alessio
    Bovis, Francesca
    Carmisciano, Luca
    Sormani, Maria Pia
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 57
  • [24] Impact of Anti-CD20 therapies on the immune homeostasis of gastrointestinal mucosa and their relationship with de novo intestinal bowel disease in multiple sclerosis: a review
    Quesada-Simo, A.
    Garrido-Marin, A.
    Nos, P.
    Gil-Perotin, S.
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [25] COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases
    Baker, D.
    Roberts, C. A. K.
    Pryce, G.
    Kang, A. S.
    Marta, M.
    Reyes, S.
    Schmierer, K.
    Giovannoni, G.
    Amor, S.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2020, 202 (02): : 149 - 161
  • [26] Should anti-CD20 be used as an immune reconstitution therapy?
    Smets, Ide
    Wokke, Beatrijs
    Smolders, Joost
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (02) : 308 - 310
  • [27] New Advances in Disease-Modifying Therapies for Relapsing and Progressive Forms of Multiple Sclerosis
    Vidal-Jordana, Angela
    NEUROLOGIC CLINICS, 2018, 36 (01) : 173 - +
  • [28] Progressive multifocal leukoencephalopathy in anti-CD20 and other monoclonal antibody (mAb) therapies used in multiple sclerosis: A review
    Sharma, Kanika
    Tolaymat, Sarah
    Yu, Hongxuyang
    Elkhooly, Mahmoud
    Jaiswal, Shruti
    Jena, Anek
    Kakara, Mihir
    Sriwastava, Shitiz
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2022, 443
  • [29] Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis
    Roach, Charles A.
    Cross, Anne H.
    FRONTIERS IN NEUROLOGY, 2021, 11
  • [30] Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation
    Tallantyre, E. C.
    Whittam, D. H.
    Jolles, S.
    Paling, D.
    Constantinesecu, C.
    Robertson, N. P.
    Jacob, A.
    JOURNAL OF NEUROLOGY, 2018, 265 (05) : 1115 - 1122
12345